Pharmaceutical Executive-02-01-2012

Brand of the Year : Abbott's Humira

For a rendering to be effective, the right balance must be struck between captivating art and accurate science.

State tech transfer laws giving universities automatic ownership of employees' inventions represent a threat to pharma partnerships-but the Supreme Court is poised to intervene in the industry's favor.

Brazil's clinical trial research is the country's backbone.

Pharm Exec speaks to Bausch + Lomb CEO Brent Saunders about how he turned around "a very troubled company".

A new generation of products for inflammatory disease is coming forward, promising better promise and possibly a cure.

Brazil was the last country to enter the fiscal crisis, but also the first to exit. And with a burgeoning middle class and a staunch commitment to national development, its pharmaceutical future is now.

Brazilian industry is learning to spread its pharma manufacturing around more.

After two years of waiting, FDA issued the first in a series of planned guidelines on social media at the end of last year. We look at some of the experts' reactions.

Sarah Krug asks if it is time for pharma companies to appoint a Chief Patient Officer, a new position designed to build an accord around patient trust.

Astellas makes its presence felt in Brazil.

French-based Besins is a relatively new entrant to the Brazilian pharma market.

Will expanded markets and ACOs offset higher rebates, added fees, and closer scrutiny of marketing and prices?

Pharm Exec's Brand of the Year: Abbott's Humira

The EU's Innovative Medicines Initiative is helping to invigorate new drug development, but there are still many hurdles to tackle before its promise is realized.

Torrent's affiliate in Brazil has become the India-based company's biggest.

Time to stop and think about CMS's 'Proposed Rule' on transparency and what it means for the life sciences business model.

Biominas helps foster the development of biotech-related businesses in Brazil.